EE
Therapeutic Areas
MeMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MeMed BV | Bacterial vs Viral Infection Differentiation | Commercial |
| MeMed Severity | Risk Stratification for Acute Infection Deterioration | CE‑marked / FDA‑clearance pending |
| MeMed Key | Platform for Multiplex Protein Measurement | Commercial |
Leadership Team at MeMed
BH
Barak Hershkovitz, MD
Chief Technology Officer
AR
Ariel Rubashkin
Chief Financial Officer
TB
Troy Boutelle, MBA
President, USA
TG
Tanya Gottlieb, MBA, PhD
Vice President, Scientific Affairs
DA
Dalia Argaman
Vice President, Regulatory Affairs & Quality Assurance
HR
Haim Regev
Vice President, International
OH
Ori Hadomi
Chairman of the Board